Core Viewpoint - The stock of Kaili Medical (300633) has shown mixed performance with a slight increase in price, but significant outflows from major funds indicate potential concerns about investor confidence [1][2]. Group 1: Stock Performance - As of December 17, 2025, Kaili Medical's stock closed at 26.62 yuan, up 0.41% with a turnover rate of 0.48% and a trading volume of 20,600 shares, amounting to a transaction value of 54.51 million yuan [1]. - On December 17, 2025, the net outflow of major funds was 191.2 thousand yuan, accounting for 3.51% of the total transaction value, while retail investors saw a net inflow of 106.28 thousand yuan, representing 1.95% of the total [1]. Group 2: Financial Metrics - Kaili Medical's total market capitalization is 11.519 billion yuan, which is above the industry average of 10.779 billion yuan, ranking 27th out of 125 companies in the medical device sector [2]. - The company reported a net profit of 33.51 million yuan for the first three quarters of 2025, a decrease of 69.25% year-on-year, while its main revenue increased by 4.37% to 1.459 billion yuan [2]. - The gross profit margin stands at 60.36%, significantly higher than the industry average of 51.02%, while the net profit margin is only 2.3%, much lower than the industry average of 9.59% [2]. Group 3: Analyst Ratings - In the last 90 days, 15 institutions have rated Kaili Medical, with 10 giving a "buy" rating and 5 an "accumulate" rating, indicating a generally positive outlook among analysts [3]. - The average target price set by institutions over the past 90 days is 41.28 yuan, suggesting potential upside from the current trading price [3].

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Kaili Medical (300633) as of December 16, 2025, with a closing price of 26.51 yuan, reflecting a slight increase of 0.11% [1] - The company reported a main revenue of 1.459 billion yuan for the first three quarters of 2025, showing a year-on-year increase of 4.37%, while the net profit attributable to shareholders decreased by 69.25% to 33.51 million yuan [2] - In Q3 2025, the company achieved a single-quarter main revenue of 495 million yuan, up 28.42% year-on-year, but reported a net loss of 13.52 million yuan, which is an increase of 78.05% in losses compared to the previous year [2] Group 2 - The company's debt ratio stands at 24.22%, with investment income of 2.08 million yuan and financial expenses of -38.30 million yuan, indicating a significant financial burden [2] - The gross profit margin for Kaili Medical is reported at 60.36%, suggesting a strong profitability potential despite the decline in net profit [2] - Over the past 90 days, 15 institutions have rated the stock, with 10 giving a buy rating and 5 an increase rating, while the average target price set by institutions is 4.128 billion yuan [2]

Core Insights - The article highlights the acceleration of business development (BD) activities in the medical device sector from September to November 2025, with a total of 58 transactions identified across various subfields, including cardiovascular, nuclear medicine, and AI-enabled devices [2][3][4]. Group 1: Mergers and Acquisitions - Mergers and acquisitions have become a prominent form of BD, with companies leveraging capital control and product integration for rapid market positioning [7][8]. - Notable acquisitions include HeartLink's $680 million all-stock acquisition of Micro-Invasive Cardiology, enhancing its structural heart disease and rhythm management capabilities [7]. - Hua'an Zhonghui's acquisition of Bangni Medical marks its entry into the absorbable suture market, indicating a shift in surgical instrument competition towards material innovation [7]. Group 2: Strategic Collaborations - Strategic partnerships have been formed during the China International Import Expo, with companies like Shanghai Pharmaceuticals collaborating with international giants such as Boston Scientific and Medtronic to enhance their supply chain and academic promotion systems [7][8]. - The collaboration between GuoYao Medical and BDI Medical aims to deepen market penetration in the biomedicine and medical device sectors, focusing on compliance and distribution channel construction [13]. Group 3: Cross-Border Cooperation - Cross-border transactions have become more active, with foreign companies establishing local R&D and production systems in China, while domestic firms are exporting their solutions globally [9][10]. - The partnership between Trasis SA and Beijing Pait Biotechnology to establish a joint venture reflects a trend towards localized production and phased integration in the Chinese market [12]. Group 4: Ecosystem Building and Channel Expansion - The integration of supply chains and ecosystem building is a key theme, with companies focusing on collaborative agreements to enhance their market presence [11][15]. - The collaboration between Baxter and Neusoft Medical aims to create a comprehensive surgical solution by integrating their respective technologies [12]. Group 5: AI and Smart Healthcare - AI and data-driven approaches are becoming central to BD collaborations, with companies increasingly focusing on smart healthcare solutions [16][17]. - The partnership between Kefu Medical and Tencent Cloud to develop AI-powered hearing aids exemplifies the trend of integrating technology into healthcare products [21]. Group 6: Research and Diagnostic Synergy - The frequency of research-oriented collaborations is rising, indicating a shift from manufacturing-driven to research-driven industry dynamics [18][19]. - The collaboration between BGI and Infinera to enhance clinical applications of sequencing technology highlights the growing importance of research in driving innovation in the medical device sector [21].

上市企业：开立医疗（300633） 相关企业：波科国际医疗贸易（上海）有限公司、飞利浦医疗器械（上海）有限公司、深圳北芯生命科 技股份有限公司、天津恒宇医疗科技有限公司、全景恒升（北京）科学技术有限公司、上海博动医疗科 技股份有限公司、深圳市赛禾医疗技术有限公司、深圳微创踪影医疗装备有限公司、苏州博动戎影医疗 科技有限公司、西安华峰医疗科技有限公司 关键词：血管内超声（IVUS）系统市场政策、血管内超声（IVUS）系统产业链图谱、血管内超声 （IVUS）系统采购规模、血管内超声（IVUS）系统竞争格局、血管内超声（IVUS）系统发展趋势 一、概述 内容概要：我国心血管疾病发病率随人口老龄化不断攀升，在冠脉介入手术中，血管内超声（IVUS） 系统能精准评估斑块、指导支架植入，降低术后不良事件发生率，其临床价值已获广泛认可，除传统冠 脉领域外， IVUS在主动脉瓣置换术术前评估、外周动脉疾病诊疗等场景的应用也在逐步拓展，此外， 随着临床医生对精准医疗的重视程度不断提升，IVUS能清晰呈现血管壁结构和病变细节，有效降低介 入手术的并发症风险，其临床价值已得到广泛认可，目前三级医院已形成IVUS常规使用规范，基层医 ...

Investment Rating - Industry investment rating is "Outperform" compared to the market, expecting the industry index to perform better than the CSI 300 index by more than 5% in the next six months [22]. Core Insights - The medical device bidding environment remains robust, with a significant trend towards high-end products. Since 2025, the release of equipment update policy dividends has led to sustained market demand growth, keeping bidding activities at a high level. Monthly procurement scales from July to November 2025 were 13.4 billion, 14.6 billion, 16.4 billion, 16.4 billion, and 20.9 billion respectively, with year-on-year growth rates of +24%, +31%, +2%, +14%, and +0% [3][11]. - The bidding environment is benefiting leading companies in the industry, with procurement scales for ultrasound, CT, MRI, DR, DSA, and gastrointestinal endoscopes showing significant year-on-year growth in November 2025 [4][12][14]. - The report emphasizes the importance of high-end and intelligent medical devices, suggesting that leading domestic companies like Mindray, United Imaging, Kaili Medical, and Aohua Endoscopy should be closely monitored for their strategic positioning in the market [5][20]. Summary by Sections Market Trends - The medical device market is experiencing a strong revival, with a notable focus on high-end imaging equipment such as CT, MRI, and ultrasound, which together account for nearly 62% of the total bidding amount [3][11]. - In November 2025, the procurement scale for ultrasound was 2.301 billion (yoy +17%), CT was 2.605 billion (yoy +26%), MRI was 2.394 billion (yoy +6%), DR was 460 million (yoy +50%), and DSA was 1.016 billion (yoy +4%) [12][14]. Company Performance - Domestic companies are aligning with industry trends, with Mindray achieving 1.318 billion (yoy +12%), United Imaging at 1.433 billion (yoy +30%), Kaili Medical at 247 million (yoy +62%), and Aohua at 109 million (yoy +60%) in November 2025 [17]. Investment Recommendations - The report recommends focusing on domestic leading enterprises that are enhancing their high-end and intelligent product offerings, as the bidding environment is expected to remain favorable due to ongoing policy support for equipment updates [5][20].

证券日报网讯 12月11日晚间，开立医疗发布公告称，公司决定将向特定对象发行股份的募投项目"松山 湖开立医疗器械产研项目"达到预定可使用状态日期由2025年12月31日调整至2026年12月31日，"总部基 地建设项目"调整至2027年12月31日，项目实施主体、募集资金投资用途及投资规模均不变。 （文章来源：证券日报） ...

证券日报网讯 12月11日晚间，开立医疗发布公告称，2025 年 12 月 10 日，公司第四届董事会第十三次 会议和第四届监事会第十二次会议，分别审议通过了《关于取消监事会、修订并办理工商变更登记的议 案》。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Kaili Medical (300633) as of December 11, 2025, with a closing price of 26.23 yuan, reflecting a decline of 2.16% [1] - The company reported a main revenue of 1.459 billion yuan for the first three quarters of 2025, an increase of 4.37% year-on-year, while the net profit attributable to shareholders decreased by 69.25% to 33.51 million yuan [2] - In Q3 2025, the company achieved a single-quarter main revenue of 495 million yuan, up 28.42% year-on-year, but reported a net loss of 13.52 million yuan, which is an increase of 78.05% in losses compared to the previous year [2] Group 2 - The company has a debt ratio of 24.22% and reported investment income of 2.08 million yuan, with financial expenses amounting to -38.30 million yuan, and a gross profit margin of 60.36% [2] - Over the past 90 days, 15 institutions have provided ratings for the stock, with 10 buy ratings and 5 hold ratings, and the average target price set by institutions is 4.128 billion yuan [2] - On December 11, 2025, the net inflow of main funds was 1.12 million yuan, accounting for 1.48% of the total transaction amount, while retail investors saw a net inflow of 1.57 million yuan, representing 2.06% of the total transaction amount [1]

深圳开立生物医疗科技股份有限公司 年报信息披露重大差错责任追究制度 深圳开立生物医疗科技股份有限公司 年报信息披露重大差错责任追究制度 第一章 总则 第一条 为进一步提高深圳开立生物医疗科技股份有限公司（以下简称"公 司"）的规范运作水平，加大对年报信息披露责任人的问责力度，提高年报信息 披露的质量和透明度，增强年报信息披露的真实性、准确性、完整性和及时性， 根据《中华人民共和国证券法》、《中华人民共和国会计法》、《上市公司信息披露 管理办法》、《上市公司治理准则》、《深圳证券交易所创业板股票上市规则》、《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》、《关 于要求制定上市公司年报信息披露重大差错责任追究制度的通知》等法律、法规、 规范性文件及《深圳开立生物医疗科技股份有限公司章程》（以下简称"《公司 章程》"）、《深圳开立生物医疗科技股份有限公司信息披露制度》（以下简称"《信 息披露管理制度"》）的有关规定，结合公司的实际情况，特制定本制度。 第二条 公司财务总监、财务会计人员、各部门负责人及其他相关人员应当 严格执行《企业会计准则》及相关规定，严格遵守公司与财务报告相关的内部控 ...

深圳开立生物医疗科技股份有限公司 董事会提名委员会工作细则 第一章 总则 第一条 为规范公司董事及高级管理人员的选聘，优化董事会组成，进一步建 立健全深圳开立生物医疗科技股份有限公司（以下简称"公司"）董事及其他高 级管理人员的考核和薪酬管理制度，完善公司治理结构，根据《中华人民共和国公 司法》（以下简称"公司法"）、《上市公司治理准则》（以下简称"治理准 则"）、《深圳证券交易所创业板股票上市规则》（以下简称"创业板上市规 则"）、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》（以下简称"规范运作"）、《上市公司独立董事管理办法》（以下简 称"独立董事管理办法"）和《深圳开立生物医疗科技股份有限公司章程》（以 下简称"公司章程"）及其他有关规定，公司特设董事会提名委员会，并制订本 工作细则。 第二条 提名委员会是董事会设立的专门工作机构，主要负责对公司董事和 高级管理人员的人选、选择标准和程序提出建议。 第三条 本细则所称董事是指在公司领取薪酬的董事，其他高级管理人员是指 董事会聘任的总经理、副总经理、董事会秘书和财务负责人。 第二章 人员组成 深圳开立生物医疗科技股份有限公司 ...